<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37735654</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care.</ArticleTitle><Pagination><StartPage>363</StartPage><MedlinePgn>363</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">363</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-023-03049-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Some patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) go on to experience post-COVID-19 condition or long COVID. Preliminary findings have given rise to the theory that long COVID may be due in part to a deranged immune response. In this study, we assess whether there is an association between SARS-CoV-2 infection and the incidence of immune-mediated inflammatory diseases (IMIDs).</AbstractText><AbstractText Label="METHODS">Matched cohort study using primary care electronic health record data from the Clinical Practice Research Datalink Aurum database. The exposed cohort included 458,147 adults aged 18&#xa0;years and older with a confirmed SARS-CoV-2 infection and no prior diagnosis of IMIDs. They were matched on age, sex, and general practice to 1,818,929 adults with no diagnosis of confirmed or suspected SARS-CoV-2 infection. The primary outcome was a composite of any of the following IMIDs: autoimmune thyroiditis, coeliac disease, inflammatory bowel disease (IBD), myasthenia gravis, pernicious anaemia, psoriasis, rheumatoid arthritis (RA), Sjogren's syndrome, systemic lupus erythematosus (SLE), type 1 diabetes mellitus (T1DM), and vitiligo. The secondary outcomes were each of these conditions separately. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for the primary and secondary outcomes, adjusting for age, sex, ethnic group, smoking status, body mass index, relevant infections, and medications.</AbstractText><AbstractText Label="RESULTS">Six hundred and nighty six (0.15%) and 2230 (0.12%) patients in the exposed and unexposed cohort developed an IMID during the follow-up period over 0.29 person-years, giving a crude incidence rate of 4.59 and 3.65 per 1000 person-years, respectively. Patients in the exposed cohort had a 22% increased risk of developing an IMID, compared to the unexposed cohort (aHR 1.22, 95% CI 1.12 to 1.33). The incidence of three IMIDs was significantly associated with SARS-CoV-2 infection. These were T1DM (aHR 1.56, 1.09 to 2.23), IBD (aHR 1.36, 1.18 to 1.56), and psoriasis (1.23, 1.05 to 1.42).</AbstractText><AbstractText Label="CONCLUSIONS">SARS-CoV-2 was associated with an increased incidence of IMIDs including T1DM, IBD and psoriasis. However, these findings could be potentially due to ascertainment bias. Further research is needed to replicate these findings in other populations and to measure autoantibody profiles in cohorts of individuals with COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Syed</LastName><ForeName>Umer</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>Anuradhaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. A.Subramanian@bham.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wraith</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham Biomedical Research Centre, University Hospital Birmingham and University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Janet M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>NIHR Birmingham Biomedical Research Centre, University Hospital Birmingham and University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGee</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghokale</LastName><ForeName>Krishna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nirantharakumar</LastName><ForeName>Krishnarajah</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroon</LastName><ForeName>Shamil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_20050</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>VAC_</Acronym><Agency>Versus Arthritis</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091369">Immunomodulating Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091369" MajorTopicYN="N">Immunomodulating Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cohort study</Keyword><Keyword MajorTopicYN="N">Immune-mediated inflammatory diseases</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>SH reports receiving funding from NIHR and UKRI. US report no competing interests.&#xa0;AS has no declarations during the study period; after the study was completed, she has&#xa0;taken a post in AstraZeneca. JL receives grant funding from NIHR, UKRI, Versus Arthritis, The Scar Free Foundation, FOREUM, and Bayer Healthcare for which also she acts as a consultant.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>1</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37735654</ArticleId><ArticleId IdType="pmc">PMC10512476</ArticleId><ArticleId IdType="doi">10.1186/s12916-023-03049-5</ArticleId><ArticleId IdType="pii">10.1186/s12916-023-03049-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141&#x2013;154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int. Accessed 19 Apr 2022.</Citation></Reference><Reference><Citation>Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155&#x2013;162. doi: 10.1097/BOR.0000000000000776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000776</ArticleId><ArticleId IdType="pmc">PMC7880581</ArticleId><ArticleId IdType="pubmed">33332890</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke MJ, del Rio C. Long COVID has exposed medicine's blind-spot. Lancet Infect Dis. 2021;21(8):1062&#x2013;1064. doi: 10.1016/S1473-3099(21)00333-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00333-9</ArticleId><ArticleId IdType="pmc">PMC8213360</ArticleId><ArticleId IdType="pubmed">34153235</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the longterm effects of COVID-19 NICE; 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Gaughan C. Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. Newport: Office for National Statistics; 2021.</Citation></Reference><Reference><Citation>The L. Understanding long COVID: a modern medical challenge. Lancet. 2021;398(10302):725. doi: 10.1016/S0140-6736(21)01900-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01900-0</ArticleId><ArticleId IdType="pmc">PMC8389978</ArticleId><ArticleId IdType="pubmed">34454656</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283&#x2013;288. doi: 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876. doi: 10.1126/scitranslmed.abd3876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;95.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K-T, Hsu B-C, Chen D-Y. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol. 2021;12:645013. doi: 10.3389/fimmu.2021.645013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.645013</ArticleId><ArticleId IdType="pmc">PMC7994612</ArticleId><ArticleId IdType="pubmed">33777042</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 &#x2013; a systematic review of the literature. J Autoimmun. 2021;117:102592. doi: 10.1016/j.jaut.2020.102592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102592</ArticleId><ArticleId IdType="pmc">PMC7833462</ArticleId><ArticleId IdType="pubmed">33401171</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res. 2020;68(5):310&#x2013;313. doi: 10.1007/s12026-020-09152-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-020-09152-6</ArticleId><ArticleId IdType="pmc">PMC7499017</ArticleId><ArticleId IdType="pubmed">32946016</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305&#x2013;310. doi: 10.1097/PRS.0b013e318219c171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e318219c171</ArticleId><ArticleId IdType="pmc">PMC3124652</ArticleId><ArticleId IdType="pubmed">21701348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48(6):1740&#x2013;g. doi: 10.1093/ije/dyz034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz034</ArticleId><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>Gokhale KM, Chandan JS, Toulis K, Gkoutos G, Tino P, Nirantharakumar K. Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies. Eur J Epidemiol. 2021;36(2):165&#x2013;78. doi: 10.1007/s10654-020-00677-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-020-00677-6</ArticleId><ArticleId IdType="pmc">PMC7987616</ArticleId><ArticleId IdType="pubmed">32856160</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;vesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087. doi: 10.1136/bmj.b5087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b5087</ArticleId><ArticleId IdType="pubmed">20228141</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A, Sridharan A, Prakash S, Agrawal H. Dendritic cells and aging: consequences for autoimmunity. Expert Rev Clin Immunol. 2012;8(1):73&#x2013;80. doi: 10.1586/eci.11.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eci.11.77</ArticleId><ArticleId IdType="pmc">PMC3285507</ArticleId><ArticleId IdType="pubmed">22149342</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Patarroyo MJ, Rodriguez-Rodriguez A, Montoya-Ortiz G. How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis. 2012;2012:251730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3238350</ArticleId><ArticleId IdType="pubmed">22195277</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeson PB. Age and sex associations of 40 autoimmune diseases. Am J Med. 1994;96(5):457&#x2013;462. doi: 10.1016/0002-9343(94)90173-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(94)90173-2</ArticleId><ArticleId IdType="pubmed">8192178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600&#x2013;609. doi: 10.2353/ajpath.2008.071008.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.071008</ArticleId><ArticleId IdType="pmc">PMC2527069</ArticleId><ArticleId IdType="pubmed">18688037</ArticleId></ArticleIdList></Reference><Reference><Citation>Calixto OJ, Anaya JM. Socioeconomic status. The relationship with health and autoimmune diseases. Autoimmun Rev. 2014;13(6):641&#x2013;54. doi: 10.1016/j.autrev.2013.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2013.12.002</ArticleId><ArticleId IdType="pubmed">24418307</ArticleId></ArticleIdList></Reference><Reference><Citation>Versini M, Jeandel P-Y, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13(9):981&#x2013;1000. doi: 10.1016/j.autrev.2014.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.07.001</ArticleId><ArticleId IdType="pubmed">25092612</ArticleId></ArticleIdList></Reference><Reference><Citation>Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus. 2006;15(11):737&#x2013;745. doi: 10.1177/0961203306069344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306069344</ArticleId><ArticleId IdType="pubmed">17153844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119&#x2013;125. doi: 10.1016/S1568-9972(03)00006-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1568-9972(03)00006-5</ArticleId><ArticleId IdType="pubmed">12848952</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev. 2012;11(6):A386&#x2013;A392. doi: 10.1016/j.autrev.2011.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.11.012</ArticleId><ArticleId IdType="pubmed">22142547</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses. 2019;11(8):762. doi: 10.3390/v11080762.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11080762</ArticleId><ArticleId IdType="pmc">PMC6723519</ArticleId><ArticleId IdType="pubmed">31430946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussein HM, Rahal EA. The role of viral infections in the development of autoimmune diseases. Crit Rev Microbiol. 2019;45(4):394&#x2013;412. doi: 10.1080/1040841X.2019.1614904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1040841X.2019.1614904</ArticleId><ArticleId IdType="pubmed">31145640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ara&#xfa;jo-Fern&#xe1;ndez S, Ahij&#xf3;n-Lana M, Isenberg DA. Drug-induced lupus: including anti-tumour necrosis factor and interferon induced. Lupus. 2014;23(6):545&#x2013;553. doi: 10.1177/0961203314523871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314523871</ArticleId><ArticleId IdType="pubmed">24557776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011;34(5):357&#x2013;374. doi: 10.2165/11588500-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11588500-000000000-00000</ArticleId><ArticleId IdType="pubmed">21513360</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE). Obesity: identifying, assessing and managing obesity in adults, young people and children. 2014. https://www.nice.org.uk/guidance/cg189. Accessed 25 Apr 2022</Citation></Reference><Reference><Citation>Nassar M, Nso N, Baraka B, Alfishawy M, Mohamed M, Nyabera A, et al. The association between COVID-19 and type 1 diabetes mellitus: a systematic review. Diabetes Metab Syndr. 2021;15(1):447&#x2013;454. doi: 10.1016/j.dsx.2021.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.02.009</ArticleId><ArticleId IdType="pmc">PMC7872855</ArticleId><ArticleId IdType="pubmed">33592371</ArticleId></ArticleIdList></Reference><Reference><Citation>Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity. 2008;41(1):11&#x2013;18. doi: 10.1080/08916930701619169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930701619169</ArticleId><ArticleId IdType="pubmed">18176860</ArticleId></ArticleIdList></Reference><Reference><Citation>ten Bergen LL, Petrovic A, Aarebrot AK, Appel S. Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol. 2020;92(4):e12945. doi: 10.1111/sji.12945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12945</ArticleId><ArticleId IdType="pubmed">32697368</ArticleId></ArticleIdList></Reference><Reference><Citation>Joossens S, Vermeire S, Van Steen K, Godefridis G, Claessens G, Pierik M, et al. Pancreatic autoantibodies in inflamm bowel dis. Inflamm Bowel Dis. 2004;10(6):771&#x2013;777. doi: 10.1097/00054725-200411000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00054725-200411000-00012</ArticleId><ArticleId IdType="pubmed">15626896</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J, Kirke-Wade E. Coronavirus: a history of English lockdown laws. London: The Commons Library. 2021. https://commonslibrary.parliament.uk/research-briefings/cbp-9068/. Accessed 17 Aug 2023.</Citation></Reference><Reference><Citation>House of Commons Health and Social Care Committee. Clearing the backlog caused by the pandemic. London: UK Parliament; 2021. https://committees.parliament.uk/publications/8352/documents/85020/default. Accessed 18 Aug 2023</Citation></Reference><Reference><Citation>Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228&#x2013;2233. doi: 10.1172/JCI78088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI78088</ArticleId><ArticleId IdType="pmc">PMC4518692</ArticleId><ArticleId IdType="pubmed">25893595</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency. The effectiveness of vaccination against long COVID A rapid evidence briefing. London: UK HSA; 2022. https://www.icpcovid.com/sites/default/files/2022-02/Ep%20241-9%20UK%20Health%20Security%20Agency%20The%20effectiveness%20of%20vaccination%20against%20long%20COVID%20Feb%202022.pdf. Accessed 18 Aug 2023</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>